CoChat
Sign Up
Cited by 111Traumatic Brain Injury and Neurovascular DisturbancesTraumatic Brain Injury ResearchAutomotive and Human Injury Biomechanics

The DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.

Cytoskeletal protein degradation and neurodegeneration evolves differently in males and females following experimental head injury

Kupina, Nancy C, Detloff, Megan R, Bobrowski, Walter F, Snyder, Bradley J, Hall, Edward D·2003·Experimental Neurology
DOI 10.1016/s0014-4886(02)00048-1
Open this paper in CoChat — free account

Abstract

The resulting neuropathological degeneration that occurs following a traumatic brain injury (TBI) is a consequence of both immediate and secondary neurochemical sequelae. Proteolysis of cytoskeletal proteins, triggered by calcium-mediated events, is believed to be a particularly significant contributor to TBI-induced neuronal death. To date, efforts to associate cytoskeletal degradation and neurodegeneration in TBI have been primarily qualitative or semiquantitative. The objectives of this study were (1). to quantitatively describe, over a posttraumatic time course, the relationship and mechanisms of cytoskeletal degradation (Western blot) and neurodegeneration (silver staining) in male and female mice following a moderately severe weight-drop impact-acceleration head injury; (2). to evaluate gender differences in the response to TBI; and (3). to examine the potential therapeutic window for future pharmacological treatment strategies. In male and female mice, we report a close correlation in the time courses of neurofilament M protein degradation and alpha-spectrin breakdown products (SBDP 150 and 145) with the peak magnitude of neurodegeneration, as quantified by silver staining. Evidence from the increased patterns of SBDPs suggests that both calpain and caspase-3 are involved. In general, males incurred peak protein degradation and neurodegeneration within 3 days after injury, while in females this did not occur until 14 days. The neuroprotective effects of estrogen are believed to be key factors in the superior outcome of female vs male mice following TBI. In mice, the therapeutic window of opportunity for pharmacological intervention aimed at limiting cytoskeletal degradation might be as much as 24 h following injury. Evidence of a protracted time course of cytoskeletal degradation, especially in females, suggests a potential for an extended treatment-duration following TBI.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0014-4886(02)00048-1

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 6

  1. Kannel, W.B., Thorn, T.J., 1994, in: Alexander, R.C.S.R.W. (Ed.), The Heart: The incidence, prevalence and mortality of cardiovascular disease, McGraw–Hill, New York
  2. McIntosh, 1996, Neuropathological sequelae of traumatic brain injury, Lab. Invest., 74, 315
  3. Roof, 1994, Lipid peroxidation is reduced and integrity of the BBB improved with progesterone treatment after CNS injury, Neurotrauma, 11, 124
  4. Verity, 1992, Ca2+-dependent processes as mediators of neurotoxicity, Neurotoxicology, 13, 139
  5. Watters, 1997, Rapid membraine effects of steroids in neuroblastoma cells, Endocrinology, 138, 4030, 10.1210/en.138.9.4030 · DOI
  6. Wise, 2001, Minireview, Endocrinology, 142, 969, 10.1210/en.142.3.969 · DOI

Cited by

Sorted by citations

See all 111

Related

See all

Metadata

Authors
Kupina, N. C., Detloff, M. R., Bobrowski, W. F., Snyder, B. J., & Hall, E. D.
Affiliations
Pfizer (United States) (US)
Corresponding author
Hall, Edward D
ORCID
Detloff, Megan R
Venue
Experimental Neurology
Publisher
Elsevier BV
Published
2003-03
Volume
180
Issue
1
Pages
55-73
ISSN
0014-4886 (ISSN-L)
DOI
10.1016/s0014-4886(02)00048-1
OpenAlex
W2007922486
Cited by
111
References
84
Citations by year
2026: 1 · 2025: 5 · 2024: 1 · 2023: 5 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 6 · 2018: 4 · 2017: 2 · 2016: 3 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 9
FWCI
5.63
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Experimental Neurology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury and Neurovascular Disturbances
  • Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
  • Physical Sciences › Engineering › Biomedical Engineering › Automotive and Human Injury Biomechanics
Keywords
traumatic brain injury, neurodegeneration, sex differences, neurofilament M, calpain, caspase-3, estrogen neuroprotection, therapeutic window, neuronal cell death
MeSH terms
Animals, Brain, Brain Injuries, Cerebral Cortex, Corpus Striatum, Cytoskeletal Proteins, Densitometry, Disease Models, Animal, Female, Hippocampus, Male, Sex Factors, Spectrin, Time Factors, Survival Rate, Silver Staining, Neurofilament Proteins, Disease Progression, Neurodegenerative Diseases, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review